About D-Sight

D-Sight has developed a first-in-class, non-invasive treatment for early-stage diabetic retinopathy, a leading cause of preventable blindness in working-age adults. This cost-effective solution aims to improve patient outcomes by preventing the progression of retinal neurodegenerative diseases associated with diabetes.

```xml <problem> Diabetic retinopathy, a common complication of diabetes, can lead to preventable blindness, particularly in the working-age population. Current standard-of-care therapies may have limitations and side effects, creating a need for safer and more effective early-stage interventions. The rising prevalence of diabetes globally is increasing the number of individuals at risk for developing diabetic retinopathy. </problem> <solution> D-Sight is developing a non-invasive treatment designed to prevent the progression of early-stage diabetic retinopathy. Their solution aims to address the unmet medical need for a cost-effective and safe therapy that avoids the side effects associated with existing treatments. By targeting the neurodegenerative aspects of retinal disease associated with diabetes, D-Sight hopes to improve the quality of life for diabetic patients and reduce the incidence of vision loss. The treatment is designed to be easily administered and integrated into existing clinical workflows. </solution> <features> - Non-invasive treatment approach - Focus on early-stage diabetic retinopathy - Designed to prevent retinal neurodegeneration - Aims to be cost-effective compared to current treatments - Seeks to minimize side effects and limitations of existing therapies </features> <target_audience> The primary target audience includes diabetic patients at risk of or in the early stages of developing diabetic retinopathy, as well as ophthalmologists and healthcare providers specializing in diabetic eye care. </target_audience> ```

What does D-Sight do?

Where is D-Sight located?

D-Sight is based in Barcelona, Spain.

When was D-Sight founded?

D-Sight was founded in 2023.

How much funding has D-Sight raised?

D-Sight has raised 1100000.

Location

Barcelona, Spain

Founded

2023

Funding

1100000

Employees

3 employees

Major Investors

Clave

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

D-Sight

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

dsight.es 500+

Crunchbase

Founded 2023 – Barcelona, Spain

Funding

Estimated Funding

$1M+

Major Investors

Clave

Team (<5)

No team information available.

Company Description

Problem

Diabetic retinopathy, a common complication of diabetes, can lead to preventable blindness, particularly in the working-age population. Current standard-of-care therapies may have limitations and side effects, creating a need for safer and more effective early-stage interventions. The rising prevalence of diabetes globally is increasing the number of individuals at risk for developing diabetic retinopathy.

Solution

D-Sight is developing a non-invasive treatment designed to prevent the progression of early-stage diabetic retinopathy. Their solution aims to address the unmet medical need for a cost-effective and safe therapy that avoids the side effects associated with existing treatments. By targeting the neurodegenerative aspects of retinal disease associated with diabetes, D-Sight hopes to improve the quality of life for diabetic patients and reduce the incidence of vision loss. The treatment is designed to be easily administered and integrated into existing clinical workflows.

Features

Non-invasive treatment approach

Focus on early-stage diabetic retinopathy

Designed to prevent retinal neurodegeneration

Aims to be cost-effective compared to current treatments

Seeks to minimize side effects and limitations of existing therapies

Target Audience

The primary target audience includes diabetic patients at risk of or in the early stages of developing diabetic retinopathy, as well as ophthalmologists and healthcare providers specializing in diabetic eye care.